인다논 유도체, 이의 약학적으로 허용되는 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
    33.
    发明公开
    인다논 유도체, 이의 약학적으로 허용되는 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 有权
    INDANONE衍生物,其药学上可接受的盐或其光学异构体,其制备方法和药物组合物,用于预防或治疗包含其中的活性成分的病毒

    公开(公告)号:KR1020120139605A

    公开(公告)日:2012-12-27

    申请号:KR1020120065022

    申请日:2012-06-18

    Abstract: PURPOSE: A novel indanone derivative, a method for preparing the same, and a pharmaceutical composition containing the same are provided to ensure low cytotoxicity and to ensure excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus, and rhino virus. CONSTITUTION: An indanone derivative is denoted by chemical formula 1. A method for preparing the indanone derivative comprises acylation or alkylation of a compound of chemical formula 1 in a base and a solvent to prepare a compound of chemical formula 1a. A method for preparing the indanone derivative comprises: a step of reacting the compound of chemical formula 1 with thionyl chloride or oxalic chloride under the presence of the base and solvent; a step of reacting the resultant with ammonium to prepare a compound of chemical formula 2; and a step of acylation or alkylation of the compound of chemical formula 2 under the presence of the base and solvent to prepare a compound of chemical formula 1b. A pharmaceutical composition for preventing or treating viral diseases contains the indanone derivative of chemical formula 1, pharmaceutically acceptable salt thereof or optical isomer thereof as an active ingredient. [Reference numerals] (AA,BB) Step 1; (CC) Step 2

    Abstract translation: 目的:提供一种新的茚酮衍生物,其制备方法和含有该化合物的药物组合物,以确保低细胞毒性并确保针对小核糖核酸病毒如柯萨奇病毒,肠道病毒,回波病毒,脊髓灰质炎病毒和犀牛病毒的优异的抗病毒活性。 构成:茚酮衍生物由化学式1表示。制备茚酮衍生物的方法包括在碱和溶剂中化学式1的化合物的酰化或烷基化以制备化学式1a的化合物。 制备茚酮衍生物的方法包括:在碱和溶剂的存在下使化学式1的化合物与亚硫酰氯或草酰氯反应的步骤; 使所得物与铵反应以制备化学式2的化合物的步骤; 以及在碱和溶剂的存在下化学式2的化合物进行酰化或烷基化的步骤,以制备化学式1b的化合物。 用于预防或治疗病毒性疾病的药物组合物含有化学式1的茚酮衍生物,其药学上可接受的盐或其光学异构体作为活性成分。 (附图标记)(AA,BB)步骤1; (CC)步骤2

Patent Agency Ranking